SCHEMBL3197948

SCHEMBL3197948

[c]1ccc2c(n1)CCCN2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
CYP11B2 P19099 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
HTT P42858 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GRIA1 P42261 1/20 0.30
GRIA2 P42262 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7834953 0.88
SCHEMBL337488 0.70 PNMT (0.34)
SCHEMBL4242922 0.69
SCHEMBL171558 0.69 NNMT (0.35) KDM4EMAPTCA12CA1CA2
SCHEMBL19153670 0.69 UHRF1 (0.41) KDM4EMAPTCA12CA1CA2
SCHEMBL4141897 0.69 OR51E2 (0.32)
SCHEMBL307955 0.68 BCHE (0.35) KDM4EMAPTCA12CA1CA2
SCHEMBL29620683 0.68 BCHE (0.35) KDM4EMAPTCA12CA1CA2
SCHEMBL2562257 0.68 KDM4E (0.33) KDM4EMAPTCA12CA1CA2
SCHEMBL156197 0.67 ADRA2A (0.35) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558607-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-03 EP claimed
US-20040122016-A1 Compositions useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-06-24 US claimed
WO-2004041813-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-05-21 WO claimed
US-7655446-B2 Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-02-02 US disclosed
US-20090036654-A1 Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED 2009-02-05 US disclosed
EP-1558607-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-03 EP disclosed
US-20040122016-A1 Compositions useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-06-24 US disclosed
WO-2004041813-A1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122016-A1 Compositions useful as inhibitors of rock and other protein kinases ROCK1, ROCK2, PRKCH KDM4E 2286/4885MAPT 617/4885CA12 3810/4885
US-20090036654-A1 Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof ROCK1, CIT, ROCK2 KDM4E 2307/4885MAPT 1588/4885CA12 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.